PL2120932T3 - Indazolowe pochodne jako inhibitory kinazy do leczenia raka - Google Patents
Indazolowe pochodne jako inhibitory kinazy do leczenia rakaInfo
- Publication number
- PL2120932T3 PL2120932T3 PL07857632T PL07857632T PL2120932T3 PL 2120932 T3 PL2120932 T3 PL 2120932T3 PL 07857632 T PL07857632 T PL 07857632T PL 07857632 T PL07857632 T PL 07857632T PL 2120932 T3 PL2120932 T3 PL 2120932T3
- Authority
- PL
- Poland
- Prior art keywords
- cancer
- treatment
- kinase inhibitors
- indazole derivatives
- indazole
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 125000003453 indazolyl group Chemical class N1N=C(C2=C1C=CC=C2)* 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06126701 | 2006-12-20 | ||
| PCT/EP2007/063998 WO2008074749A1 (en) | 2006-12-20 | 2007-12-14 | Indazole derivatives as kinase inhibitors for the treatment of cancer |
| EP07857632.9A EP2120932B1 (en) | 2006-12-20 | 2007-12-14 | Indazole derivatives as kinase inhibitors for the treatment of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2120932T3 true PL2120932T3 (pl) | 2015-02-27 |
Family
ID=39245139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL07857632T PL2120932T3 (pl) | 2006-12-20 | 2007-12-14 | Indazolowe pochodne jako inhibitory kinazy do leczenia raka |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8114865B2 (pl) |
| EP (1) | EP2120932B1 (pl) |
| JP (1) | JP5302896B2 (pl) |
| CN (1) | CN101594862B (pl) |
| AU (1) | AU2007336335B8 (pl) |
| BR (1) | BRPI0720589A2 (pl) |
| CA (1) | CA2673095C (pl) |
| DK (1) | DK2120932T3 (pl) |
| EA (1) | EA017852B1 (pl) |
| ES (1) | ES2509820T3 (pl) |
| MX (1) | MX2009006401A (pl) |
| PL (1) | PL2120932T3 (pl) |
| PT (1) | PT2120932E (pl) |
| SI (1) | SI2120932T1 (pl) |
| WO (1) | WO2008074749A1 (pl) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7638541B2 (en) | 2006-12-28 | 2009-12-29 | Metabolex Inc. | 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine |
| CA2693169C (en) * | 2007-07-19 | 2016-01-12 | Metabolex, Inc. | N-linked heterocyclic receptor agonists for the treatment of diabetes and metabolic disorders |
| EA018503B1 (ru) | 2007-07-20 | 2013-08-30 | НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. | Замещенные производные индазола, активные как ингибиторы киназы |
| US8354399B2 (en) * | 2008-12-18 | 2013-01-15 | Nerviano Medical Sciences S.R.L. | Substituted indazole derivatives active as kinase inhibitors |
| AR078411A1 (es) | 2009-05-07 | 2011-11-09 | Lilly Co Eli | Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende |
| CN102666553B (zh) | 2009-10-01 | 2015-05-06 | 赛马拜制药公司 | 取代的四唑-1-基-苯氧基甲基-噻唑-2-基-哌啶基-嘧啶盐 |
| US9180127B2 (en) | 2009-12-29 | 2015-11-10 | Dana-Farber Cancer Institute, Inc. | Type II Raf kinase inhibitors |
| CN103080093A (zh) * | 2010-03-16 | 2013-05-01 | 达纳－法伯癌症研究所公司 | 吲唑化合物及其应用 |
| WO2012075318A2 (en) * | 2010-12-01 | 2012-06-07 | Cell Signaling Technology, Inc. | Fn1 and alk gene translocations in cancer and alk kinase expression in ovarian cancer |
| FR2970967B1 (fr) | 2011-01-27 | 2013-02-15 | Pf Medicament | Derives de type azaindazole ou diazaindazole comme medicament |
| DK2707359T3 (en) * | 2011-05-12 | 2017-01-23 | Nerviano Medical Sciences Srl | SUBSTITUTED INDAZOLD DERIVATIVES ACTIVE AS KINase INHIBITORS |
| US9056867B2 (en) | 2011-09-16 | 2015-06-16 | Novartis Ag | N-substituted heterocyclyl carboxamides |
| CA2856291C (en) | 2011-11-17 | 2020-08-11 | Dana-Farber Cancer Institute, Inc. | Inhibitors of c-jun-n-terminal kinase (jnk) |
| ES2755719T3 (es) * | 2012-04-05 | 2020-04-23 | Nerviano Medical Sciences Srl | Nuevos agentes alquilantes |
| JP6231556B2 (ja) * | 2012-05-23 | 2017-11-15 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Ｎ−［５−（３，５−ジフルオロ−ベンジル）−１ｈ−インダゾール−３−イル］−４−（４−メチル−ピペラジン−１−イル）−２−（テトラヒドロ−ピラン−４−イルアミノ）−ベンズアミドの調製方法 |
| KR101936851B1 (ko) * | 2012-07-16 | 2019-01-11 | 한국과학기술연구원 | 단백질 키나아제 저해제인 신규 피라졸로피리딘 유도체 또는 인다졸 유도체 |
| EP2689778A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindoles or diazaindoles for treating pain |
| EP2689779A1 (en) | 2012-07-27 | 2014-01-29 | Pierre Fabre Medicament | Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk |
| CN113679717A (zh) | 2012-08-22 | 2021-11-23 | 康奈尔大学 | 用于抑制肌成束蛋白的方法 |
| EP2909194A1 (en) | 2012-10-18 | 2015-08-26 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| US9758522B2 (en) | 2012-10-19 | 2017-09-12 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged small molecules as inducers of protein degradation |
| WO2014063054A1 (en) | 2012-10-19 | 2014-04-24 | Dana-Farber Cancer Institute, Inc. | Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof |
| AU2014337122B2 (en) | 2013-10-18 | 2019-01-03 | Dana-Farber Cancer Institute, Inc. | Heteroaromatic compounds useful for the treatment of proliferative diseases |
| US10047070B2 (en) | 2013-10-18 | 2018-08-14 | Dana-Farber Cancer Institute, Inc. | Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7) |
| WO2015110467A1 (en) * | 2014-01-23 | 2015-07-30 | Nerviano Medical Sciences S.R.L. | Process for the preparation of substituted n-(5-benzenesulfonyl-1h-indazol-3-yl)-benzamides |
| CA2940144C (en) | 2014-02-20 | 2023-06-13 | Cornell University | Substituted indazol-3-yl derivatives and pharmaceutical compositions thereof useful as inhibitor of fascin |
| TWI672141B (zh) * | 2014-02-20 | 2019-09-21 | 美商醫科泰生技 | 投予ｒｏｓ１突變癌細胞之分子 |
| US9862688B2 (en) | 2014-04-23 | 2018-01-09 | Dana-Farber Cancer Institute, Inc. | Hydrophobically tagged janus kinase inhibitors and uses thereof |
| WO2015164614A1 (en) | 2014-04-23 | 2015-10-29 | Dana-Farber Cancer Institute, Inc. | Janus kinase inhibitors and uses thereof |
| CN107207471B (zh) * | 2014-12-02 | 2020-06-26 | 伊尼塔公司 | 用于治疗神经母细胞瘤的组合 |
| WO2016096709A1 (en) | 2014-12-16 | 2016-06-23 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
| EP3236959B1 (en) | 2014-12-23 | 2025-09-24 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 (cdk7) |
| CN104530045A (zh) * | 2015-01-14 | 2015-04-22 | 中国药科大学 | 吡唑并[4,3-c]四氢吡啶类c-Met激酶抑制剂及其制备方法和用途 |
| WO2016123629A1 (en) * | 2015-01-30 | 2016-08-04 | Vanderbilt University | Indazole and azaindazole substituted compounds as mglur4 allosteric potentiators, compositions, and methods of treating neurological dysfunction |
| AU2016243529B2 (en) | 2015-03-27 | 2021-03-25 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| EP4019515A1 (en) | 2015-09-09 | 2022-06-29 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| JP7061068B2 (ja) | 2015-12-18 | 2022-04-27 | イグナイタ インコーポレイテッド | 癌治療のための併用薬 |
| JP2019527693A (ja) | 2016-08-03 | 2019-10-03 | サイマベイ・セラピューティクス・インコーポレイテッドＣｙｍａＢａｙ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 炎症性胃腸疾患または胃腸状態を治療するためのオキシメチレンアリール化合物 |
| CN121401264A (zh) | 2017-07-19 | 2026-01-27 | 伊尼塔公司 | 包括恩曲替尼的药物组合物 |
| BR112020003292A2 (pt) | 2017-08-16 | 2020-08-18 | Vanderbilt University | compostos indazol como potencializadores alostéricos de mglur4 e seus usos terapêuticos, bem como composição farmacêutica e método para fabricação de medicamento para potenciar a atividade do receptor mglur4 |
| WO2019077506A1 (en) | 2017-10-17 | 2019-04-25 | Ignyta, Inc. | PHARMACEUTICAL COMPOSITIONS AND SOLID GALENIC FORMS |
| CN110452176A (zh) * | 2018-05-07 | 2019-11-15 | 四川大学 | 吲唑类衍生物及其制备方法和用途 |
| JP7590185B2 (ja) | 2018-06-25 | 2024-11-26 | ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド | Ｔａｉｒｅファミリーキナーゼインヒビターおよびそれらの使用 |
| AU2019413694B2 (en) | 2018-12-28 | 2025-03-20 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinase 7 and uses thereof |
| EP3725777A1 (en) * | 2019-04-17 | 2020-10-21 | Rottapharm Biotech S.r.l. | Benzo- and pyrido-pyrazoles as protein kinase inhibitors |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2357502T3 (es) * | 2001-09-26 | 2011-04-27 | Pfizer Italia S.R.L. | Derivados de aminoindazol activos como inhibidores de quinasa, procedimiento para su preparación y composiciones farmaceuticas que los contienen. |
| FR2836915B1 (fr) * | 2002-03-11 | 2008-01-11 | Aventis Pharma Sa | Derives d'aminoindazoles, procede de preparation et intermediaires de ce procede a titre de medicaments et compositions pharmaceutiques les renfermant |
| TW200501960A (en) * | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
| JP4617299B2 (ja) * | 2003-03-03 | 2011-01-19 | アレイ バイオファーマ、インコーポレイテッド | ｐ３８阻害剤及びその使用法 |
| FR2871158A1 (fr) | 2004-06-04 | 2005-12-09 | Aventis Pharma Sa | Indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
| AU2006218403A1 (en) * | 2005-03-03 | 2006-09-08 | Sirtris Pharmaceuticals, Inc. | Fused heterocyclic compounds and their use as sirtuin modulators |
| AR071780A1 (es) * | 2008-05-15 | 2010-07-14 | Nerviano Medical Sciences Srl | Derivados de carbamoilo de carbonilamino-pirazoles biciclicos como profarmacos |
-
2007
- 2007-12-14 ES ES07857632.9T patent/ES2509820T3/es active Active
- 2007-12-14 WO PCT/EP2007/063998 patent/WO2008074749A1/en not_active Ceased
- 2007-12-14 BR BRPI0720589-9A patent/BRPI0720589A2/pt active Search and Examination
- 2007-12-14 SI SI200731506T patent/SI2120932T1/sl unknown
- 2007-12-14 US US12/520,387 patent/US8114865B2/en active Active
- 2007-12-14 EA EA200970595A patent/EA017852B1/ru not_active IP Right Cessation
- 2007-12-14 CA CA2673095A patent/CA2673095C/en not_active Expired - Fee Related
- 2007-12-14 AU AU2007336335A patent/AU2007336335B8/en not_active Ceased
- 2007-12-14 EP EP07857632.9A patent/EP2120932B1/en active Active
- 2007-12-14 JP JP2009542015A patent/JP5302896B2/ja active Active
- 2007-12-14 MX MX2009006401A patent/MX2009006401A/es active IP Right Grant
- 2007-12-14 DK DK07857632.9T patent/DK2120932T3/da active
- 2007-12-14 CN CN200780049818.0A patent/CN101594862B/zh active Active
- 2007-12-14 PL PL07857632T patent/PL2120932T3/pl unknown
- 2007-12-14 PT PT78576329T patent/PT2120932E/pt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2509820T3 (es) | 2014-10-20 |
| JP2010530840A (ja) | 2010-09-16 |
| WO2008074749A9 (en) | 2009-05-07 |
| EP2120932B1 (en) | 2014-07-09 |
| CN101594862B (zh) | 2015-11-25 |
| AU2007336335B2 (en) | 2013-05-30 |
| AU2007336335A2 (en) | 2009-08-06 |
| US20100197665A1 (en) | 2010-08-05 |
| EA017852B1 (ru) | 2013-03-29 |
| AU2007336335A8 (en) | 2014-07-24 |
| CA2673095A1 (en) | 2008-06-26 |
| WO2008074749A1 (en) | 2008-06-26 |
| EA200970595A1 (ru) | 2010-02-26 |
| PT2120932E (pt) | 2014-10-10 |
| AU2007336335B8 (en) | 2014-07-24 |
| BRPI0720589A2 (pt) | 2014-02-25 |
| SI2120932T1 (sl) | 2014-09-30 |
| EP2120932A1 (en) | 2009-11-25 |
| AU2007336335A1 (en) | 2008-06-26 |
| MX2009006401A (es) | 2009-06-23 |
| JP5302896B2 (ja) | 2013-10-02 |
| CN101594862A (zh) | 2009-12-02 |
| DK2120932T3 (da) | 2014-10-13 |
| CA2673095C (en) | 2016-03-15 |
| US8114865B2 (en) | 2012-02-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL2120932T3 (pl) | Indazolowe pochodne jako inhibitory kinazy do leczenia raka | |
| HUS2000049I1 (hu) | Kináz aktivitással rendelkezõ helyettesített imidazol származékok | |
| ZA201000085B (en) | 2-oxo-3-benzyl-benzoxazol-2-one derivatives and related compounds as Met kinase inhibitors for the treatment of tumors | |
| EP2063897A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
| EP2063896A4 (en) | KINASEHEMMER FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
| IL202317A0 (en) | Polycyclic indazole derivatives and their use as erk inhibitors for the treatment of cancer | |
| EP2057158B8 (en) | Triazole derivatives as kinase inhibitors | |
| IL198247A0 (en) | Indazole derivatives useful as l-cpt1 inhibitors | |
| ZA200908624B (en) | 5-heteroaryl substituted indazoles as kinase inhibitors | |
| IL196202A0 (en) | Indazole derivatives for the treatment of hsp90-induced diseases | |
| EP2211615A4 (en) | PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS | |
| IL201650A0 (en) | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases | |
| IL206394A0 (en) | 2-benzylpyridazinone derivatives as met kinase inhibitors | |
| IL199323A (en) | Converted Pirazolo-Quinazoline History, Process for Preparation and Use as Kinase Inhibitors | |
| EP2046333A4 (en) | THIOZOLIDINEDIONE DERIVATIVES AS INHIBITORS OF P13-KINASE | |
| ZA201005116B (en) | 6.7-dialkoxy ouinazoline derivatives useful for treatment of cancer related disorders | |
| EP1993535A4 (en) | THIAZOLONE AS A PI3 KINASE INHIBITOR | |
| ZA200904912B (en) | Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | |
| IL194491A0 (en) | Thiazolyldihydroindazole derivatives as protein kinase inhibitors | |
| EP1993536A4 (en) | THIAZOLONES AS INHIBITORS OF P13-KINASES | |
| EP1993537A4 (en) | THIAZOLONES AS INHIBITORS OF P13-KINASES | |
| ZA200902730B (en) | Pteridine derivatives as polo-like kinase inhibitors useful in the treatment of cancer | |
| ZA201009085B (en) | Dihydropyrazole derivatives as tyrosine kinase modulators for the treatment of tumors | |
| EP1891082A4 (en) | NEW INHIBITORS OF PYRUVATE KINASE AS THERAPEUTIC AGENTS AGAINST CANCER | |
| HK1139937A (en) | Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders |